Allstate Investment Management’s Biogen BIIB Stock Holding History

Allstate Investment Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$1.6M	Buy	+5,784	New	+$1.63M	0.05%	240

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Allstate Investment Management's BIIB Position: Q4 2022 in Review

Allstate Investment Management opened a new position in Biogen (BIIB) in Q4 2022: 5,784 shares worth $1.6M. The stake represents 0.05% of the portfolio and ranks #240 among its holdings.

1,031 funds tracked by Wall St. Rank hold BIIB as of Q4 2022.

Allstate Investment Management held 5,784 shares of Biogen worth $1.6M as of Q4 2022.
Biogen was a new Allstate Investment Management position in Q4 2022.
Biogen made up 0.05% of Allstate Investment Management's portfolio in Q4 2022, its #240 holding.
1,031 funds tracked by Wall St. Rank held Biogen as of Q4 2022.

Based on Allstate Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.